Advanced search
Publication Cover
Future Cardiology Volume 2, 2006 - Issue 3
Submit an article Journal homepage
76
Views
0
CrossRef citations to date
0
Altmetric
Review

Pathogenetic Potential of Antiphospholipid Antibodies

Panayiotis G Vlachoyiannopoulosa Department of Pathophysiology Medical School National University of Athens75 Mikras Asias Street115 27AthensGreece. Tel 302107462663; Fax 302107462664; [email protected]
&
Michael Samarkosb Department of Pathophysiology Medical School National University of Athens75 Mikras Asias Street115 27AthensGreece Tel 302107462663; Fax 302107462664;
Pages 303-314 | Published online: 11 May 2006

Bibliography

  • McNeil HP , SimpsonRJ, ChestermanCN, KrilisSA: Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β 2-glycoprotein I (apolipoprotein H).Proc. Natl Acad. Sci. USA, 87(11), 4120–4124 (1990).
  • Galli M , ComfuriusP, MaassenCet al..: Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet, 335(8705), 1544–1547 (1990).
  • Bevers EM , GalliM, BarbuiT, ComfuriusP, ZwaalRF: Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin.Thromb. Haemost., 66(6), 629–632 (1991).
  • Nakamura N , KuragakiC, ShidaraY, YamajiK, WadaY: Antibody to annexin V has anti-phospholipid and lupus anticoagulant properties.Am. J. Hematol., 49(4), 347–348 (1995).
  • Passam F , KrilisS: Laboratory tests for the antiphospholipid syndrome: current concepts.Pathology, 36(2), 129–138 (2004).
  • Favaloro EJ , SilvestriniR, MohammedA: Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach.Pathology, 31(2), 142–147 (1999).
  • Tincani A , AllegriF, SanmarcoMet al..: Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations – a cooperative project of the European Antiphospholipid Forum. Thromb. Haemost., 86(2), 575–583 (2001).
  • Tincani A , AllegriF, BalestrieriGet al..: Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb. Res., 114(5–6), 553–558 (2004).
  • Wong R , FavaloroE, PollockWet al..: A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays. Pathology, 36(2), 182–192 (2004).
  • Loizou S , McCreaJD, RudgeAC, Reynolds R, Boyle CC, Harris EN: Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin. Exp. Immunol., 62(3), 738–745 (1985).
  • Arvieux J , RousselB, JacobMC, Colomb MG: Measurement of anti-phospholipid antibodies by ELISA using β 2-glycoprotein I as an antigen. J. Immunol. Methods, 143(2), 223–229 (1991).
  • Arvieux J , DarnigeL, CaronC, ReberG, BensaJC, ColombMG: Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants.Thromb. Haemost., 74(4), 1120–1125 (1995).
  • Brandt JT , TriplettDA, AlvingB, ScharrerI: Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH.Thromb. Haemost., 74(4), 1185–1190 (1995).
  • Arnout J : Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants.Thromb. Haemost., 86(1), 83–91 (2001).
  • Cervera R , PietteJC, FontJet al..: Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum., 46(4), 1019–1027 (2002).
  • Asherson RA : A “primary” antiphospholipid syndrome?J. Rheumatol., 15(12), 1742–1746 (1988).
  • Nochy D , DaugasE, DrozDet al..: The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J. Am. Soc. Nephrol., 10(3), 507–518 (1999).
  • Miyakis S , LockshinMD, AtsumiTet al..: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb.Haemost., 4(2), 295–306 (2006).
  • Daugas E , NochyD, Huong du LT et al.: Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J. Am. Soc. Nephrol., 13(1), 42–52 (2002).
  • Vlachoyiannopoulos PG , KanellopoulosP, TektonidouM, MoutsopoulosHM: Renal involvement in antiphospholipid syndrome.Nephrol. Dial. Transplant., 16(Suppl. 6) 60–62 (2001).
  • Tektonidou MG , SotsiouF, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM: Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum., 50(8), 2569–2579 (2004).
  • Vlachoyiannopoulos PG , Kanellopoulos PG, Ioannidis JP, Tektonidou MG, Mastorakou I, Moutsopoulos HM: Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology (Oxford), 42(5), 645–651 (2003).
  • Vlachoyiannopoulos PG , SamarkosM: Peripheral vascular disease in antiphospholipid syndrome.Thromb. Res., 114(5–6), 509–519 (2004).
  • Ford PM , FordSE, LillicrapDP: Association of lupus anticoagulant with severe valvular heart disease in systemic lupus erythematosus.J. Rheumatol., 15(4), 597–600 (1988).
  • Tektonidou MG , IoannidisJP, Moyssakis I et al.: Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome. Ann. Rheum. Dis., 60(1), 43–48 (2001).
  • Asherson RA , KhamashtaMA, BaguleyE, OakleyCM, RowellNR, HughesGR: Myocardial infarction and antiphospholipid antibodies in SLE and related disorders.Q. J. Med., 73(272), 1103–1115 (1989).
  • Tektonidou MG , MalagariK, VlachoyiannopoulosPG, KelekisDA, MoutsopoulosHM: Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging.Arthritis Rheum., 48(3), 732–736 (2003).
  • Furie B ,FurieBC: Molecular basis of blood coagulation. In:Hematology, 4th Edition. Hoffman R, Benz EJ Jr, Shattil SJ (Eds), Churchill Livingstone, New York, NY, USA (2005).
  • Galli M , LucianiD, BertoliniG, Barbui T: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood, 101(5), 1827–1832 (2003).
  • Galli M , LucianiD, BertoliniG, Barbui T: Anti-β 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood, 102(8), 2717–2723 (2003).
  • George J , AfekA, GilburdBet al..: Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus, 6(9), 723–729 (1997).
  • Olee T , PierangeliSS, HandleyHHet al..: A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Proc. Natl Acad. Sci. USA, 93(16), 8606–8611 (1996).
  • Pierangeli SS , BarkerJH, StikovacDet al..: Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb. Haemost., 71(5), 670–674 (1994).
  • Blank M , TincaniA, ShoenfeldY: Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies.J. Rheumatol., 21(1), 100–104 (1994).
  • Bakimer R , FishmanP, BlankM, Sredni B, Djaldetti M, Shoenfeld Y: Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J. Clin. Invest., 89(5), 1558–1563 (1992).
  • Holers VM , GirardiG, MoLet al..: Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med., 195(2), 211–220 (2002).
  • Garcia CO , Kanbour-ShakirA, TangH, MolinaJF, EspinozaLR, GharaviAE: Induction of experimental antiphospholipid antibody syndrome in PL/J mice following immunization with β 2 GPI.Am. J. Reprod. Immunol., 37(1), 118–124 (1997).
  • Aron AL , CuellarML, BreyRLet al..: Early onset of autoimmunity in MRL/++ mice following immunization with β 2 glycoprotein I. Clin. Exp. Immunol., 101(1), 78–81 (1995).
  • Blank M , FadenD, TincaniAet al..: Immunization with anticardiolipin cofactor (β-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J. Autoimmun., 7(4), 441–455 (1994).
  • Shoenfeld Y : Induction of experimental primary and secondary antiphospholipid syndromes in naive mice.Am. J. Reprod. Immunol., 28(3–4), 219–221 (1992).
  • Gharavi AE , SammaritanoLR, WenJ, ElkonKB: Induction of antiphospholipid autoantibodies by immunization with β 2 glycoprotein I (apolipoprotein H).J. Clin. Invest., 90(3), 1105–1109 (1992).
  • Igarashi K , UmedaM, TokitaS, NamKS, InoueK: Effective induction of anti-phospholipid and anticoagulant antibodies in normal mouse.Thromb. Res., 61(2), 135–148 (1991).
  • Asherson RA : Acute respiratory distress syndrome and other unusual manifestations of the catastrophic antiphospholipid (Asherson’s) syndrome.Isr. Med. Assoc. J., 6(6), 360–363 (2004).
  • Robertson SA , RobertsCT, van Beijering E et al.: Effect of β2-glycoprotein I null mutation on reproductive outcome and antiphospholipid antibody-mediated pregnancy pathology in mice. Mol. Hum. Reprod., 10(6), 409–416 (2004).
  • Ichinose A , McMullenBA, FujikawaK, DavieEW: Amino acid sequence of the β subunit of human Factor XIII, a protein composed of ten repetitive segments.Biochemistry, 25(16), 4633–4638 (1986).
  • Nicholson-Weller A , ZaiaJ, RaumMG, ColiganJE: Decay accelerating factor (DAF) peptide sequences share homology with a consensus sequence found in the superfamily of structurally related complement proteins and other proteins including haptoglobin, factor XIII, β 2-glycoprotein I and the IL-2 receptor.Immunol. Lett., 14(4), 307–311 (1987).
  • Lorand L , MaldonadoN, FraderaJ, Atencio AC, Robertson B, Urayama T: Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (Factor XIII). Br. J. Haematol., 23(1), 17–27 (1972).
  • Lorand L , VelascoPT, RinneJR, Amare M, Miller LK, Zucker ML: Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (Factor XIII) system. Proc. Natl Acad. Sci. USA, 85(1), 232–236 (1988).
  • Fukue H , AndersonK, McPhedranP, Clyne L, McDonagh J: A unique Factor XIII inhibitor to a fibrin-binding site on Factor XIIIA. Blood, 79(1), 65–74 (1992).
  • Milner GR , HoltPJ, BottomleyJ, Maciver JE: Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to Factor XIII. J. Clin. Pathol., 30(8), 770–773 (1977).
  • Lorand L , VelascoPT, HillJM, Hoffmeister KJ, Kaye FJ: Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against actor XIII. Thromb. Haemost., 88(6), 919–923 (2002).
  • Sjober K , ErikssonS, TenngartB, RothEB, LefflerH, StenbergP: Factor XIII and tissue transglutaminase antibodies in coeliac and inflammatory bowel disease.Autoimmunity, 35(5), 357–364 (2002).
  • Chiarantini E , ValanzanoR, LiottaAAet al..: Persistence of hemostatic alterations in patients affected by Crohn’s disease after bowel surgery. Thromb. Res., 87(6), 539–546 (1997).
  • Korochkin IM , VerbitskaiaIA, TugutovAN, MiagkovaMA, PolevaiaOI: Thrombin and anti-thrombin antibody levels in the blood of patients with acute myocardial infarction.Kardiologiia, 30(1), 45–48 (1990).
  • Costa JM , FiessingerJN, CapronL, Aiach M: Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosis. Thromb. Haemost., 67(2), 193–199 (1992).
  • Hwang KK , GrossmanJM, VisvanathanSet al..: Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J. Immunol., 167(12), 7192–7198 (2001).
  • Fleck RA , RapaportSI, RaoLV: Anti-prothrombin antibodies and the lupus anticoagulant.Blood, 72(2), 512–519 (1988).
  • Oosting JD , DerksenRH, BobbinkIW, HackengTM, BoumaBN, de Groot PG: Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood, 81(10), 2618–2625 (1993).
  • Galli M , BerettaG, DaldossiM, BeversEM, BarbuiT: Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies.Thromb. Haemost., 77(3), 486–491 (1997).
  • Field SL , ChestermanCN, HoggPJ: Dependence on prothrombin for inhibition of activated protein C activity by lupus antibodies.Thromb.Haemost., 84(6), 1132–1133 (2000).
  • Nojima J , KuratsuneH, SuehisaEet al..: Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br. J. Haematol., 118(2), 577–583 (2002).
  • Simmelink MJ , HorbachDA, DerksenRHet al..: Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br. J. Haematol., 113(3), 621–629 (2001).
  • Galli M , WillemsGM, RosingJet al..: Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of Factor Va by activated protein C. Br. J. Haematol., 129(2), 240–247 (2005).
  • Ieko M , YasukouchiT, SawadaKI, Koike T: The influence of β2-glycoprotein I on tissue factor activity. Semin. Thromb. Hemost., 24(3), 211–215 (1998).
  • Jacobson DM , LewisJH, BontempoFA, SperoJA, RagniMV, ReinmuthOM: Recurrent cerebral infarctions in two brothers with antiphospholipid antibodies that block coagulation reactions.Stroke, 17(1), 98–102 (1986).
  • Clyne LP , FarberLR, ChopykRL: Procainamide-induced circulating anticoagulants in a congenitally-deficient Factor XI patient.Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch., 116(2), 239–244 (1989).
  • Schousboe I , RasmussenMS: Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by β2-glycoprotein I and anti-β 2-glycoprotein I.Thromb. Haemost., 73(5), 798–804 (1995).
  • Jones DW , GallimoreMJ, HarrisSL, WinterM: Antibodies to factor XII associated with lupus anticoagulant.Thromb.Haemost., 81(3), 387–390 (1999).
  • Jones DW , GallimoreMJ, MacKieIJ, Harris SL, Winter M: Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br. J. Haematol., 110(3), 721–726 (2000).
  • Jones DW , MacKieIJ, GallimoreMJ, WinterM: Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome.Br. J. Haematol., 113(2), 550–552 (2001).
  • Takeuchi R , AtsumiT, IekoM, AmasakiY, IchikawaK, KoikeT: Suppressed intrinsic fibrinolytic activity by monoclonal anti-β-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome.Br. J. Haematol., 119(3), 781–788 (2002).
  • Shi T , IversonGM, QiJCet al..: β 2-glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped β 2-glycoprotein I. Proc. Natl Acad. Sci. USA, 101(11), 3939–3944 (2004).
  • Shi T , GiannakopoulosB, IversonGM, CockerillKA, LinnikMD, KrilisSA: Domain V of β2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317–Thr318.J. Biol. Chem., 280(2), 907–912 (2005).
  • Yang Q , ShiT, CheyneB, Giannakopoulos B, Krillis SA: Anti-β2-glycoprotein I antibodies potentiate the inhibitory effects of β2-glycoprotein I on the activation of FXI by FIIa: effect on clipped β2-glycoprotein I. Thromb. Res., 114, 608 (2004).
  • Patrassi GM , SartoriMT, RuffattiAet al..: Fibrinolytic pattern in recurrent spontaneous abortions: no relationship between hypofibrinolysis and anti-phospholipid antibodies. Am. J. Hematol., 47(4), 266–272 (1994).
  • Ruiz-Arguelles GJ , Ruiz-ArguellesA, Lobato-MendizabalEet al..: Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus. Am. J. Hematol., 37(1), 9–13 (1991).
  • Cugno M , DominguezM, CabibbeMet al..: Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Br. J. Haematol., 108(4), 871–875 (2000).
  • Ieko M , SawadaKI, KoikeTet al..: The putative mechanism of thrombosis in antiphospholipid syndrome: impairment of the protein C and the fibrinolytic systems by monoclonal anticardiolipin antibodies. Semin. Thromb. Hemost., 25(5), 503–507 (1999).
  • Ieko M , IchikawaK, AtsumiTet al..: Effects of β2-glycoprotein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis. Semin. Thromb. Hemost., 26(1), 85–90 (2000).
  • Yang CD , HwangKK, YanWet al..: Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J. Immunol., 172(9), 5765–5773 (2004).
  • Atsumi T , KhamashtaMA, AndujarCet al..: Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J. Rheumatol., 25(1), 69–73 (1998).
  • Hudson M , HerrAL, RauchJet al..: The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J. Rheumatol., 30(11), 2385–2391 (2003).
  • Marciniak E , RomondEH: Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant.Blood, 74(7), 2426–2432 (1989).
  • Dahlback B , CarlssonM, SvenssonPJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.Proc. Natl Acad. Sci. USA, 90(3), 1004–1008 (1993).
  • Pablos JL , CalizRA, CarreiraPEet al..: Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. J. Rheumatol., 26(3), 588–590 (1999).
  • Kassis J , NevilleC, RauchJet al..: Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis. Thromb. Haemost., 92(6), 1312–1319 (2004).
  • Gennari LC , BlancoAN, AlbertoMF, GrossoSH, PeiranoAA, LazzariMA: Antiphospholipid antibodies impact the protein C (PC) pathway behavior.Am. J. Hematol., 71(2), 128–130 (2002).
  • Martinuzzo M , ForastieroR, AdamczukY, CerratoG, CarrerasLO: Activated protein C resistance in patients with anti-β 2 glycoprotein I antibodies.Blood Coagul. Fibrinolysis, 7(7), 702–704 (1996).
  • Wu J , ZhouZ, LiXet al..: Activated protein C resistance in antiphospholipid thrombosis syndrome. Chin. Med. J. (Engl.), 113(8), 699–701 (2000).
  • Nojima J , KuratsuneH, SuehisaE, Iwatani Y, Kanakura Y: Acquired activated protein C resistance associated with IgG antibodies against β2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin. Chem., 51(3), 545–552 (2005).
  • Ruiz-Arguelles GJ , Garces-EiseleJ, Alarcon-SegoviaD, Ruiz-ArguellesA: Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome.Blood Coagul. Fibrinolysis, 7(3), 344–348 (1996).
  • Aznar J , VillaP, EspanaF, EstellesA, Grancha S, Falco C: Activated protein C resistance phenotype in patients with antiphospholipid antibodies. J. Lab. Clin. Med., 130(2), 202–208 (1997).
  • Matsuda J , GotohM, GohchiK, Kawasugi K, Tsukamoto M, Saitoh N: Resistance to activated protein C activity of an anti-β2-glycoprotein I antibody in the presence of β2-glycoprotein I. Br. J. Haematol., 90(1), 204–206 (1995).
  • Ieko M , IchikawaK, TriplettDAet al..: β2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum., 42(1), 167–174 (1999).
  • Cariou R , TobelemG, BellucciSet al..: Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells – inhibition of thrombomodulin-dependent protein C activation. Thromb. Haemost., 60(1), 54–58 (1988).
  • Oosting JD , DerksenRH, HackengTMet al..: In vitro studies of antiphospholipid antibodies and its cofactor, β2-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thromb. Haemost., 66(6), 666–671 (1991).
  • Potzsch B , KawamuraH, PreissnerKT, SchmidtM, SeeligC, Muller-BerghausG: Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant.J. Lab. Clin. Med., 125(1), 56–65 (1995).
  • Del Papa N , GuidaliL, SpatolaLet al..: Relationship between anti-phospholipid and anti-endothelial cell antibodies III: β 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin. Exp. Rheumatol., 13(2), 179–185 (1995).
  • Meroni PL , PapaND, BeltramiB, Tincani A, Balestrieri G, Krilis SA: Modulation of endothelial cell function by antiphospholipid antibodies. Lupus, 5(5), 448–450 (1996).
  • Hanly JG , HongC, IssekutzA: β 2-glycoprotein I and anticardiolipin antibody binding to resting and activated cultured human endothelial cells.J. Rheumatol., 23(9), 1543–1549 (1996).
  • George J , BlankM, LevyYet al..: Differential effects of anti-β2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation, 97(9), 900–906 (1998).
  • Pierangeli SS , Colden-StanfieldM, LiuX, BarkerJH, AndersonGL, HarrisEN: Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo.Circulation, 99(15), 1997–2002 (1999).
  • Cho CS , ChoML, ChenPPet al..: Antiphospholipid antibodies induce monocyte chemoattractant protein-1 in endothelial cells. J. Immunol., 168(8), 4209–4215 (2002).
  • Dunoyer-Geindre S , de Moerloose P, Galve-de Rochemonteix B, Reber G, Kruithof EK: NFκB is an essential intermediate in the activation of endothelial cells by anti-β(2)-glycoprotein 1 antibodies. Thromb. Haemost., 88(5), 851–857 (2002).
  • Raschi E , TestoniC, BosisioDet al..: Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood, 101(9), 3495–3500 (2003).
  • Meroni PL , BorghiMO, RaschiEet al..: Inflammatory response and the endothelium. Thromb. Res., 114(5–6), 329–334 (2004).
  • Chen Q , StonePR, WoonSTet al..: Antiphospholipid antibodies bind to activated but not resting endothelial cells: is an independent triggering event required to induce antiphospholipid antibody-mediated disease? Thromb. Res., 114(2), 101–111 (2004).
  • Hasselaar P , DerksenRH, OostingJD, BlokzijlL, de Groot PG: Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb. Haemost., 62(2), 654–660 (1989).
  • Bouma B , de Groot PG, van den Elsen JM et al.: Adhesion mechanism of human β(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J., 18(19), 5166–5174 (1999).
  • Guerin J , ShengY, ReddelS, IversonGM, ChapmanMG, KrilisSA: Heparin inhibits the binding of β2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome.J. Biol. Chem., 277(4), 2644–2649 (2002).
  • Vlachoyiannopoulos PG , MavraganiCP, BourazopoulouE, BalitsariAV, RoutsiasJG: Anti-CD40 antibodies in antiphospholipid syndrome and systemic lupus erythematosus.Thromb. Haemost., 92(6), 1303–1311 (2004).
  • Kotowicz K , DixonGL, KleinNJ, Peters MJ, Callard RE: Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin-4 selectively induces expression of vascular cell adhesion molecule-1 and P-selectin resulting in preferential adhesion of lymphocytes. Immunology, 100(4), 441–448 (2000).
  • Zhang J , McCraeKR: Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-b2 glycoprotein I antibodies.Blood, 105(5), 1964–1969 (2005).
  • Cederholm A , SvenungssonE, Jensen-Urstad K et al.: Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler. Thromb. Vasc. Biol., 25(1), 198–203 (2005).
  • Vega-Ostertag M , HarrisEN, PierangeliSS: Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin.Arthritis Rheum., 50(9), 2911–2919 (2004).
  • Martinuzzo ME , MacloufJ, CarrerasLO, Levy-ToledanoS: Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation.Thromb. Haemost., 70(4), 667–671 (1993).
  • Joseph JE , HarrisonP, MackieIJ, Isenberg DA, Machin SJ: Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br. J. Haematol., 115(2), 451–459 (2001).
  • Fanelli A , BergaminiC, RapiSet al..: Flow cytometric detection of circulating activated platelets in primary antiphospholipid syndrome. Correlation with thrombocytopenia and anticardiolipin antibodies. Lupus, 6(3), 261–267 (1997).
  • Lutters BC , DerksenRH, TekelenburgWL, LentingPJ, ArnoutJ, de Groot PG: Dimers of β2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2´. J. Biol. Chem., 278(36), 33831–33838 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.